Skip to main content
    G

    Ginkgo Bioworks Holdings (DNA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NYSE

    $11.74
    +0.21 (+1.82%)

    Market Cap: $791.92M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    40%(8/20)
    Avg Surprise
    -306.16%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.58
    Range$-0.58 - $-0.58
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.00n/a
    60d ago$0.00n/a
    30d ago$0.00n/a
    7d ago$0.00n/a
    Current$-0.58
    Revenue Consensus
    $22M
    Range$21M - $23M
    3 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.58
    Range$-0.58 - $-0.58
    1 analysts
    Revenue Consensus
    $-4353340
    Range$-7186670 - $613330
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.58---
    Sep 26EST
    		-$-0.58---
    Jun 26
    Reported Aug 5
    		$-0.86$-0.70-22.86%Miss+21.8%
    Mar 26
    Reported May 7
    		$-1.39$-1.34-3.73%Miss+17.3%
    Dec 25
    Reported Feb 26
    		$-1.42$-1.80+21.11%Beat+29.0%
    Sep 25
    Reported Nov 6
    		$-1.45$-1.24-16.94%Miss-34.3%
    Jun 25
    Reported Aug 7
    		$-1.10$-1.44+23.61%Beat+75.0%
    Mar 25
    Reported May 6
    		$-1.68$-1.77+5.08%Beat-2000.0%
    Dec 24
    Reported Feb 25
    		$-2.00$-0.06-3330.53%Miss+32.0%
    Sep 24
    Reported Nov 12
    		$-1.08N/A+67.47%Beat+70.4%
    Jun 24
    Reported Aug 8
    		$-4.40$-3.12-41.03%Miss-43.8%
    Mar 24
    Reported May 9
    		$-0.08$-0.08+0.00%Beat+97.9%
    Dec 23
    Reported Feb 29
    		$-2.94$-2.80-5.00%Miss-3166.7%
    Sep 23
    Reported Nov 8
    		$-3.65$-3.20-14.06%Miss+77.9%
    Jun 23
    Reported Aug 9
    		$-3.06$-3.50+12.57%Beat+81.4%
    Mar 23
    Reported May 10
    		$-3.89$-3.90+0.26%Beat+73.7%
    Dec 22
    Reported Mar 1
    		$-0.09N/A+57.14%Beat+90.9%
    Sep 22
    Reported Nov 14
    		$-16.51$-9.68-70.56%Miss-415.9%
    Jun 22
    Reported Aug 15
    		$-16.44$-5.44-202.21%Miss-3188.0%
    Mar 22
    Reported May 16
    		$-14.80$-7.40-100.00%Miss-49433.3%
    Dec 21
    Reported Mar 28
    		$-0.99$-0.04-2375.00%Miss-
    Sep 21
    Reported Nov 15
    		$-3.20$-1.40-128.57%Miss-
    Jun 21
    Reported Sep 20
    		$-0.50N/AN/ABeat-
    Mar 21
    Reported May 24
    		$0.03$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-2.29EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-219.60%Operating Margin-285.00%
    ROE-59.90%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest Coverage-54.64x
    Current Ratio4.57xQuick Ratio4.57x
    Trading Statistics
    Beta1.79Avg Volume3.57M
    52-Week High$18.2252-Week Low$5.37

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$12.24
    SMA 20$11.24
    SMA 50$8.80
    SMA 200$8.49
    EMA 10$11.79
    EMA 20$11.11
    EMA 50$9.72
    EMA 200$8.92

    MACD

    Line: 0.99Signal: 1.14Hist: -0.15

    ADX

    ADX: 56.4+DI: 36.1-DI: 12.6

    Aroon & PSAR

    Aroon Up72.0
    Aroon Down4.0
    PSAR$16.69

    Bollinger Bands

    Upper Band$14.79
    Lower Band$7.70
    %B Position6307%(Upper)
    Band Width0.57

    RSI (14-Day)

    Neutral
    56.0

    Momentum Oscillators

    Stoch %K25.7
    Stoch %D31.8
    Williams %R-79.8
    ROC (10d)-6.1%
    Momentum-0.76
    CCI (20d)5.3
    MFI (14d)39.9

    Volatility Measures

    ATR (14d)$1.40(11.9%)
    StdDev (20d)1.77
    Hist Vol164.0%(High)

    Volume Flow

    VWAP$11.31
    OBV16.5M
    AD Line-6.1M
    CMF (20d)0.120

    Volume Metrics

    Avg Vol (20d)3.7M
    Vol Ratio0.6x
    VWMA (20d)$11.84

    Pivot Points

    R3$12.82
    R2$12.44
    R1$11.99
    Pivot Point$11.61
    S1$11.16
    S2$10.78
    S3$10.33

    Advanced Oscillators

    TSI20.83
    Ultimate Osc53.8
    KST645.02

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$20.16M$19.47M$33.40M$38.84M$39.13M$38.23M$43.85M$89.05M$56.21M$37.94M$34.76M$55.43M
    Cost of Revenue$1.72M$3.10M$-8,505,000$12.80M$5.38M$4.09M$-11,387,000$12.00M$25.53M$18.40M$6.61M$6.92M
    Gross Profit$18.44M$16.38M$41.90M$26.04M$33.75M$34.14M$55.23M$77.04M$30.68M$19.54M$28.14M$48.51M
    Operating Expenses$76.98M$87.75M$96.85M$116.05M$91.92M$115.11M$137.83M$132.25M$265.43M$206.74M$206.26M$334.90M
    R&D$46.21M$49.92M$50.13M$69.35M$53.37M$70.92M$76.38M$77.01M$134.22M$136.46M$117.04M$156.66M
    SG&A$30.77M$37.83M$46.01M$44.95M$34.98M$39.72M$57.30M$52.29M$66.28M$70.29M$89.22M$82.03M
    Operating Income$-58,548,000$-71,374,000$-65,937,000$-90,017,000$-58,163,000$-80,972,000$-100,163,000$-55,204,000$-226,388,000$-178,002,000$-178,117,000$-286,393,000
    Interest Income$-2,686,000$-1,214,000$6.44M$3.68M$-229,000$-3,693,000$19.05M$-6,912,000$-6,826,000$-2,544,000$3.58M$-36,324,000
    Interest Expense$-3,232,000$-3,596,000$17.91M$-5,742,000$-6,083,000$-6,081,000$31.37M$-9,251,000$-10,313,000$-11,711,000$44.01M$-15,020,000
    Income Before Tax$-57,193,000$-76,139,000$-81,394,000$-80,754,000$-53,477,000$-83,222,000$-107,859,000$-56,778,000$-216,991,000$-165,880,000$-211,892,000$-302,913,000
    Income Tax Expense$128,000$-80,000$-643,000$1,000$-283,000$88,000$-325,000$-375,000$190,000$31,000$-198,000$-22,000
    Net Income$-46,710,000$-82,587,000$-80,751,000$-80,755,000$-60,300,000$-90,957,000$-107,534,000$-56,403,000$-217,181,000$-165,911,000$-211,694,000$-302,891,000
    EBITDA$-45,424,000$-65,722,000$-51,453,000$-76,012,000$-44,082,000$-70,788,000$-76,449,000$-41,948,000$-206,591,000$-162,178,000$-158,632,000$-260,549,000
    EBIT$-57,739,000$-78,521,000$-65,116,000$-90,180,000$-59,331,000$-85,610,000$-92,101,000$-59,117,000$-223,921,000$-175,047,000$-171,469,000$-281,609,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about DNA

    Government Contracts

    Gov Obligations (TTM)
    $26.59M
    Gov Obligations / Revenue
    17.6%
    Obligations YoY
    -60.5%
    Active Awards
    4
    New Awards (TTM)
    1
    Avg Remaining Term
    17.9 mo

    Top agency: Department of Health and Human Services at 95.8% of trailing twelve month obligations across 2 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    75D30126F00004Department of Health and Human ServicesCenters for Disease Control and Prevention$3.20MMay 3, 2026

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Ginkgo Bioworks CFO Steven Coen sells $36,045 in stock

    Ginkgo Bioworks CFO Steven Coen sold 2,403 shares of the company's Class A Common Stock for $36,045 at $15.00 per share on October 5, 2026. The stock currently trades significantly lower at $11.47...

    Investing.com•10/7/26•Somewhat-Bearish

    Ginkgo Bioworks CFO Steven Coen Sells 2,403 Shares Under Rule 10b5-1 Plan on October 5, 2026

    Steven P. Coen, CFO of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA), sold 2,403 shares of Class A Common Stock on October 5, 2026...

    Kalkine Media•10/7/26•Neutral

    A planned share sale leaves Ginkgo Bioworks (DNA) CFO holding 49,448 shares directly.

    Ginkgo Bioworks Holdings, Inc. CFO Steven P. Coen sold 2,403 shares of Class A Common Stock at $15 per share on October 5, 2026. This transaction was conducted under a Rule 10b5-1 sales plan. Following the sale...

    Stock Titan•10/7/26•Somewhat-Bearish

    Officer Steven P. Coen proposes selling 2,403 Ginkgo Bioworks (NYSE: DNA) shares.

    Ginkgo Bioworks officer Steven P. Coen has proposed selling 2,403 Class A shares, valued at approximately $36,045.00, through Fidelity Brokerage Services LLC, with an approximate sale date of October 5...

    Stock Titan•10/5/26•Neutral

    Ginkgo Bioworks CFO Steven Coen sells $2,302 in stock By Investing.com

    Ginkgo Bioworks CFO Steven Coen sold 330 shares of Class A Common Stock for $2,302 to cover tax withholding obligations. This transaction followed his acquisition of 743 shares through RSU vesting. The company recently...

    Investing.com South Africa•8/25/26•Somewhat-Bearish

    DNA Valuation and Fair Value

    P/E
    -2.3x
    P/B
    1.7x
    See GNG's fair value

    DNA Profitability: Margins, ROIC and FCF

    Gross margin
    91.9%
    Operating margin
    -285.0%
    Net margin
    -219.6%
    ROE
    -59.9%
    FCF margin
    -163.1%

    DNA Competitors

    CompanyTicker
    Esperion Therapeutics IncESPR
    Corvus Pharmaceuticals IncCRVS
    Ardelyx IncARDX
    Varex Imaging CorpVREX
    P3 Health Partners IncPIII
    Geron CorporationGERN
    InMode LtdINMD
    Candel Therapeutics IncCADL

    Sector: Healthcare

    DNA Analyst Ratings

    Consensus
    Sell
    Analysts
    3
    Strong Buy
    0
    Buy
    0
    Hold
    1
    Sell
    1
    Strong Sell
    1

    DNA Bull Case vs Bear Case

    Bear case

    • DNA has a -219.6% net profit margin.
    • DNA's quarterly revenue changed -48.5% year over year.
    • 66.7% of DNA's analyst ratings are Sell or Strong Sell.

    DNA Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -407.1%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.58
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 0 down

    Frequently Asked Questions About DNA

    Does DNA pay dividends?

    Ginkgo Bioworks Holdings (DNA) does not currently pay a regular dividend.

    What is DNA's market cap?

    Ginkgo Bioworks Holdings (DNA) has a market capitalization of $791.92M with a current stock price of $11.74.

    Related stocks

    Sector: Healthcare

    All stocks starting with D

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In